Analyses of treatment outcome according to age in patients with chronic myeloid leukemia receiving imatinib frontline
This study investigates outcome in different age groups of 101 imatinib frontline treated patients with chronic myeloid leukemia. Middle aged patients had a significantly higher rate of major molecular response, superior estimated 6-year event-free survival and higher rate of the estimated 6-year overall survival compared to younger and elderly patients, and consequently the best long-term treatment outcome.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: I. Ćojbašić, L. Mačukanović-Golubović, M. Vučić, I. Tijanić Tags: Original Study Source Type: research
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Gleevec | Leukemia | Lymphoma | Myeloma | Study